phrykt

PharmaCyte Biotech, Inc. (PMCB): who owns it and who trades it

As of Nov 16, 2026, PMCB insiders reported 6 purchases worth $128K in the last 12 months. The largest buyer was Joshua Silverman (CEO), with $80.3K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling PharmaCyte Biotech

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, PMCB insiders reported $128K of open-market purchases and $0 of sales.

Purchases, 12 months
$128K
6 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jan 7, 2026
Filed Jan 7, 2026

Purchases and sales by month

$128K$128KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jan 7, 2026Joshua SilvermanCEOPurchase40,000$0.83$33.2KForm 4
Jan 7, 2026Jonathan SchechterDirectorPurchase20,000$0.84$16.8KForm 4
Jan 6, 2026Joshua SilvermanCEOPurchase30,000$0.79$23.7KForm 4
Jan 6, 2026Jonathan SchechterDirectorPurchase20,000$0.79$15.8KForm 4
Jan 5, 2026Joshua SilvermanCEOPurchase30,000$0.78$23.4KForm 4
Jan 5, 2026Jonathan SchechterDirectorPurchase20,000$0.78$15.6KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Joshua SilvermanCEO and President, Director$80.3K–Jan 7, 2026
Jonathan SchechterDirector$48.2K–Jan 7, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PMCB short interest

Low short interest. 0.5% of PMCB shares are sold short: about 1 share in 212. Over the last 12 reports the number of shares short went down 89%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 50,675 PMCB shares were sold short, 0.5% of the shares outstanding, down 27.7% from the report before. At the average daily volume of 42,490 shares, buying them all back would take about 1.2 trading days (days to cover).

Shares short, % of all shares

0.47%May 15Oct 304.96%

Days to cover

1.2May 15Oct 304.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202650,6750.47%-28%42,4901.2
Oct 15, 202670,1040.65%-48%99,4231.0
Sep 30, 2026133,8851.25%+90%533,5571.0
Sep 15, 202670,4360.66%-12%238,1941.0
Aug 31, 202679,7930.74%-62%91,4121.0
Aug 14, 2026208,1611.94%-29%99,8782.1
Jul 31, 2026291,9602.72%-9%152,9961.9
Jul 15, 2026322,4103.00%-1%75,7594.3
Jun 30, 2026326,1263.04%-7%103,4733.1
Jun 15, 2026350,6163.27%-7%125,3622.8
May 29, 2026376,3783.51%-20%243,9391.5
May 15, 2026469,8984.38%+356%382,7971.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

PharmaCyte Biotech company events

PharmaCyte Biotech filed 3 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing, auditor). The latest was on Oct 16, 2026.

  1. Oct 16, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  2. Apr 2, 2026LeadershipPharmaCyte Biotech, Inc. held its annual meeting of stockholders for the year ended April 30, 2026 via live webcast. Filing
  3. Dec 5, 2025ListingPharmaCyte Biotech, Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

PharmaCyte Biotech financials

Famous investors that hold PMCB

2 of the 50 well-known investors we track reported holding PMCB in their latest 13F filing. The largest position is Ken Griffin's, worth $57.7K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026140,414$57.7K0.0%-50%
Jim Simons · Renaissance TechnologiesQ3 202664,738$26.6K0.0%+70%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about PharmaCyte Biotech, Inc. (PMCB) stock

Are PMCB insiders buying or selling?

In the last 12 months, PMCB insiders reported 6 open-market purchases worth $128K and no sales. The latest trade was on Jan 7, 2026. See every trade.

What is the short interest in PMCB?

As of Oct 30, 2026, 50,675 PMCB shares were sold short, 0.5% of the shares outstanding, down 27.7% from the report before. At the average daily volume of 42,490 shares, buying them all back would take about 1.2 trading days (days to cover). See the history.

Which famous investors hold PMCB?

2 of the 50 well-known investors we track reported PMCB in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $57.7K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.